2 No-Brainer Pharma Stocks to Buy Right Now

Many big pharma stocks have performed surprisingly well thus far in 2022, especially considering the slump that Wall Street is enduring. Case in point, both Bristol-Myers Squibb (NYSE: BMY) and Johnson & Johnson (NYSE: JNJ) have fared significantly better than the broader market and are in positive territory year to date -- despite headwinds that include geopolitical tensions, supply-chain issues, inflation, and interest rate hikes.

Of course, good share price action over the short term doesn't offer anywhere near enough data to let us draw definitive conclusions about the real health of a company. But as it turns out, both of these healthcare giants have plenty to offer long-term investors.

Continue reading

Source Fool.com